Fair and equitable subject selection in concurrent COVID-19 clinical trials

Clinical trials emerged in rapid succession as the COVID-19 pandemic created an unprecedented need for life-saving therapies. Fair and equitable subject selection in clinical trials offering investigational therapies ought to be an urgent moral concern. Subject selection determines the distribution...

Full description

Saved in:  
Bibliographic Details
Authors: Jansen, O. (Author) ; Angelos, Peter (Author) ; Schrantz, J. (Author) ; Donington, S. (Author) ; Madariaga, L. (Author) ; Zakrison, L. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2021
In: Journal of medical ethics
Year: 2021, Volume: 47, Issue: 1, Pages: 7-11
Online Access: Volltext (kostenfrei)
Volltext (kostenfrei)

MARC

LEADER 00000caa a22000002 4500
001 181616397X
003 DE-627
005 20230428063545.0
007 cr uuu---uuuuu
008 220908s2021 xx |||||o 00| ||eng c
024 7 |a 10.1136/medethics-2020-106590  |2 doi 
035 |a (DE-627)181616397X 
035 |a (DE-599)KXP181616397X 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Jansen, O.  |e VerfasserIn  |4 aut 
245 1 0 |a Fair and equitable subject selection in concurrent COVID-19 clinical trials 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Clinical trials emerged in rapid succession as the COVID-19 pandemic created an unprecedented need for life-saving therapies. Fair and equitable subject selection in clinical trials offering investigational therapies ought to be an urgent moral concern. Subject selection determines the distribution of risks and benefits, and impacts the applicability of the study results for the larger population. While Research Ethics Committees monitor fair subject selection within each trial, no standard oversight exists for subject selection across multiple trials for the same disease. Drawing on the experience of multiple clinical trials at a single academic medical centre in the USA, we posit that concurrent COVID-19 trials are liable to unfair and inequitable subject selection on account of scientific uncertainty, lack of transparency, scarcity and, lastly, structural barriers to equity compounded by implicit bias. To address the critical gap in the current literature and international regulation, we propose new ethical guidelines for research design and conduct that bolsters fair and equitable subject selection. Although the proposed guidelines are tailored to the research design and protocol of concurrent trials in the COVID-19 pandemic, they may have broader relevance to single COVID-19 trials. 
601 |a COVID-19 
700 1 |a Angelos, Peter  |e VerfasserIn  |4 aut 
700 1 |a Schrantz, J.  |e VerfasserIn  |4 aut 
700 1 |a Donington, S.  |e VerfasserIn  |4 aut 
700 1 |a Madariaga, L.  |e VerfasserIn  |4 aut 
700 1 |a Zakrison, L.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 47(2021), 1, Seite 7-11  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:47  |g year:2021  |g number:1  |g pages:7-11 
856 4 0 |u https://doi.org/10.1136/medethics-2020-106590  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/47/1/7.abstract  |x Verlag  |z kostenfrei  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185617917 
LOK |0 003 DE-627 
LOK |0 004 181616397X 
LOK |0 005 20220908053757 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-03#1478DEB4BCB0F741FADCC07733039E698A30271E 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1 
ORI |a SA-MARC-ixtheoa001.raw